Weiss Multi-Strategy Advisers’s Ascendis Pharma A/S ASND Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,002	Closed	-$235K	–	652
2022 Q1	$235K	Sell	2,002 -3,017	-60%	-$349K	0.01%	619
2021 Q4	$675K	Buy	+5,019	New	+$747K	0.02%	524
2021 Q3	–	Sell	-16,793	Closed	-$2.21M	–	672
2021 Q2	$2.21M	Buy	16,793 +9,809	+140%	+$1.31M	0.05%	393
2021 Q1	$900K	Buy	6,984 +966	+16%	+$147K	0.02%	497
2020 Q4	$1M	Sell	6,018 -4,145	-41%	-$685K	0.02%	490
2020 Q3	$1.57M	Buy	10,163 +114	+1%	+$16.4K	0.04%	375
2020 Q2	$1.49M	Buy	10,049 +5,234	+109%	+$719K	0.04%	369
2020 Q1	$542K	Sell	4,815 -185	-4%	-$24K	0.02%	338
2019 Q4	$696K	Buy	+5,000	New	+$555K	0.01%	519
2015 Q2	–	Sell	-22,000	Closed	-$382K	–	442
2015 Q1	$382K	Buy	+22,000	New	+$400K	0.02%	383

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ASND Position: Q2 2022 in Review

Weiss Multi-Strategy Advisers sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 2,002 shares — an estimated $235K sold.

Weiss Multi-Strategy Advisers first reported a position in ASND in Q1 2015 and held it in 10 quarters. The position peaked at $2.21M in Q2 2021. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

Weiss Multi-Strategy Advisers reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 2,002 Ascendis Pharma A/S shares in Q2 2022, an estimated $235K.
Weiss Multi-Strategy Advisers first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 10 quarters.
Weiss Multi-Strategy Advisers's Ascendis Pharma A/S position peaked at $2.21M in Q2 2021.
168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.